CRISPR Therapeutics AG (CRSP)
63.56
-1.70
(-2.60%)
USD |
NASDAQ |
Jun 14, 16:00
63.56
0.00 (0.00%)
After-Hours: 20:00
CRISPR Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.00% |
| September 30, 2023 | |
| June 30, 2023 | 36.23% |
| March 31, 2023 | 57.81% |
| December 31, 2022 | -113.6K% |
| September 30, 2022 | -41.24K% |
| Date | Value |
|---|---|
| June 30, 2022 | -21.37K% |
| March 31, 2022 | -17.12K% |
| December 31, 2021 | -157.7% |
| September 30, 2021 | -6.73K% |
| June 30, 2021 | 97.01% |
| March 31, 2021 | -9.77K% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-113.6K%
Minimum
Dec 2022
97.01%
Maximum
Jun 2021
-19.07K%
Average
-6.73K%
Median
Sep 2021
Gross Profit Margin (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 87.27% |
| Intellia Therapeutics Inc | -- |
| Novartis AG | 74.46% |
| MoonLake Immunotherapeutics | -- |
| Regeneron Pharmaceuticals Inc | 86.21% |